JP2022541752A5 - - Google Patents

Info

Publication number
JP2022541752A5
JP2022541752A5 JP2022501191A JP2022501191A JP2022541752A5 JP 2022541752 A5 JP2022541752 A5 JP 2022541752A5 JP 2022501191 A JP2022501191 A JP 2022501191A JP 2022501191 A JP2022501191 A JP 2022501191A JP 2022541752 A5 JP2022541752 A5 JP 2022541752A5
Authority
JP
Japan
Prior art keywords
cys
pro
phe
solvate
hydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022501191A
Other languages
English (en)
Japanese (ja)
Other versions
JP7801207B2 (ja
JP2022541752A (ja
Filing date
Publication date
Priority claimed from EP19000325.1A external-priority patent/EP3763726A1/en
Application filed filed Critical
Priority claimed from PCT/EP2020/069308 external-priority patent/WO2021005131A1/en
Publication of JP2022541752A publication Critical patent/JP2022541752A/ja
Publication of JP2022541752A5 publication Critical patent/JP2022541752A5/ja
Priority to JP2026000148A priority Critical patent/JP2026062901A/ja
Application granted granted Critical
Publication of JP7801207B2 publication Critical patent/JP7801207B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022501191A 2019-07-08 2020-07-08 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用 Active JP7801207B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026000148A JP2026062901A (ja) 2019-07-08 2026-01-05 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19000325.1A EP3763726A1 (en) 2019-07-08 2019-07-08 Compounds comprising a fibroblast activation protein ligand and use thereof
EP19000325.1 2019-07-08
EP19198810.4 2019-09-20
EP19198810 2019-09-20
PCT/EP2020/069308 WO2021005131A1 (en) 2019-07-08 2020-07-08 Compounds comprising a fibroblast activation protein ligand and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026000148A Division JP2026062901A (ja) 2019-07-08 2026-01-05 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用

Publications (3)

Publication Number Publication Date
JP2022541752A JP2022541752A (ja) 2022-09-27
JP2022541752A5 true JP2022541752A5 (enExample) 2023-07-20
JP7801207B2 JP7801207B2 (ja) 2026-01-16

Family

ID=71409440

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022501191A Active JP7801207B2 (ja) 2019-07-08 2020-07-08 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用
JP2026000148A Pending JP2026062901A (ja) 2019-07-08 2026-01-05 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026000148A Pending JP2026062901A (ja) 2019-07-08 2026-01-05 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用

Country Status (12)

Country Link
US (1) US20220315554A1 (enExample)
EP (1) EP3997104A1 (enExample)
JP (2) JP7801207B2 (enExample)
KR (1) KR20220032078A (enExample)
CN (3) CN118955620A (enExample)
AU (2) AU2020309161A1 (enExample)
BR (1) BR112022000144A2 (enExample)
CA (1) CA3145872A1 (enExample)
CL (1) CL2022000016A1 (enExample)
IL (2) IL324399A (enExample)
MX (1) MX2022000251A (enExample)
WO (1) WO2021005131A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3997103T3 (pl) 2019-07-08 2025-03-24 3B Pharmaceuticals Gmbh Związki zawierające ligand białka aktywującego fibroblasty i ich zastosowanie
EP4147053B1 (en) 2020-05-07 2026-01-28 Institut Curie Antxr1 as a biomarker of immunosuppressive fibroblast populations and its use for predicting response to immunotherapy
CN116888138A (zh) * 2020-11-30 2023-10-13 瑞择生物公司 放射性药物缀合组合物及其用途
EP4050018A1 (en) * 2021-01-07 2022-08-31 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof
GB202109922D0 (en) 2021-07-09 2021-08-25 Blue Earth Diagnostics Ltd Radiotracers and therapeutics binding to fibroblast activation protein (fap)
EP4448544A2 (en) * 2021-12-17 2024-10-23 3B Pharmaceuticals GmbH Carbonic anhydrase ix ligands
EP4475900A1 (en) 2022-02-09 2024-12-18 Novartis AG Pharmaceutical compositions comprising a 225-actinium-labelled complex and a bismuth sequestering agent
IL322552A (en) 2023-02-10 2025-10-01 Chengdu New Radiomedicine Tech Co Ltd Polypeptide compound and its use
JP2026510608A (ja) 2023-02-14 2026-04-08 ラーディオファックス ゲーエムベーハー 薬物及び処置の方法
CN118754936A (zh) * 2023-03-27 2024-10-11 晶核生物医药科技(南京)有限公司 环状多肽类化合物及其应用
EP4692105A1 (en) * 2023-03-27 2026-02-11 Bivision Pharmaceuticals, Inc Cyclic polypeptide compound and use thereof
CN118754937A (zh) * 2023-03-27 2024-10-11 晶核生物医药科技(南京)有限公司 环状多肽类化合物及其应用
CN118930606A (zh) * 2023-05-11 2024-11-12 成都纽瑞特医疗科技股份有限公司 靶向成纤维细胞活化蛋白的多肽放射性核素配合物及其应用
TW202502800A (zh) * 2023-07-11 2025-01-16 大陸商江蘇恆瑞醫藥股份有限公司 一種成纖維細胞活化蛋白配體及其用途
AU2024334645A1 (en) * 2023-08-31 2026-02-26 Stichting Radboud Universitair Medisch Centrum Endometriosis tracer
WO2025082283A1 (zh) * 2023-10-16 2025-04-24 四川科伦博泰生物医药股份有限公司 环肽结构的配体化合物及其核素标记物、药物组合物及应用
US20250186630A1 (en) 2023-12-12 2025-06-12 Viewpoint Molecular Targeting, Inc. Fibroblast activation protein targeting peptides
AU2025214491A1 (en) 2024-02-01 2026-08-06 Novartis Ag Methods for treating cancer
WO2026008525A1 (en) * 2024-07-01 2026-01-08 Bayer Aktiengesellschaft Stable radionuclide-containing formulations
WO2026017046A1 (zh) * 2024-07-19 2026-01-22 晶核生物医药科技(南京)有限公司 一种环多肽、其制备方法和应用
WO2026021314A1 (zh) * 2024-07-22 2026-01-29 山东威智知科药业有限公司 Fap化合物及其用途
WO2026041109A1 (zh) * 2024-08-23 2026-02-26 苏州博锐创合医药有限公司 成纤维细胞活化蛋白抑制剂及其用途
WO2026046340A1 (zh) * 2024-08-30 2026-03-05 江苏恒瑞医药股份有限公司 一种f-18标记反应前体分子的方法
WO2026056964A1 (zh) * 2024-09-14 2026-03-19 四川科伦博泰生物医药股份有限公司 环肽结构的配体化合物及其核素标记物、药物组合物及应用
WO2026149506A1 (zh) * 2025-01-10 2026-07-16 天津恒瑞医药有限公司 一种药物组合物及其制备方法
WO2026149529A1 (zh) * 2025-01-10 2026-07-16 天津恒瑞医药有限公司 一种成纤维细胞活化蛋白配体及其用途
WO2026163110A1 (en) 2025-01-30 2026-08-06 Novartis Ag Combinations with fap targeting compounds and conjugates thereof
CN120590466B (zh) * 2025-08-06 2026-05-12 首都医科大学脑重大疾病研究中心(北京脑重大疾病研究院) 一种靶向成纤维细胞活化蛋白的化合物及其应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4885363A (en) 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
US5021556A (en) 1987-07-22 1991-06-04 Neorx Corporation Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides
US5075099A (en) 1988-05-31 1991-12-24 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US5367080A (en) 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
US5965107A (en) 1992-03-13 1999-10-12 Diatide, Inc. Technetium-99m labeled peptides for imaging
US5886142A (en) 1997-05-20 1999-03-23 Thomas Jefferson University Radiolabeled thrombus imaging agents
JP2001518290A (ja) 1997-09-29 2001-10-16 ポイント セラピューティクス， インコーポレイテッド インビトロでの造血細胞の刺激
EP0953639A1 (en) 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
CA2401252A1 (en) 2000-03-17 2001-09-20 Boehringer Ingelheim Pharma Kg Human and humanized fap-alpha-specific antibodies
EP1452868A2 (en) * 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
US7374898B2 (en) * 2004-10-12 2008-05-20 The Research Foundation Of State University Of New York Peptide inhibitors against seprase
CA2606785A1 (en) 2005-05-19 2006-11-23 Genentech, Inc. Fibroblast activation protein inhibitor compounds and methods
US8933201B2 (en) 2006-06-07 2015-01-13 The Board Of Regents Of The University Of Oklahoma Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use
CA2681351A1 (en) 2007-03-20 2008-09-25 Trustees Of Tufts College Inhibitors of fibroblast activation protein, and methods of use thereof
EP2100900A1 (en) 2008-03-07 2009-09-16 Universitätsspital Basel Bombesin analog peptide antagonist conjugates
CN102203061A (zh) 2008-09-25 2011-09-28 分子制药洞察公司 选择性seprase抑制剂
WO2011040972A1 (en) 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd. Anti-fibroblast activation protein antibodies and methods and uses thereof
PE20171512A1 (es) 2010-08-13 2017-10-20 Roche Glycart Ag Anticuerpos anti-fap
WO2013107820A1 (en) 2012-01-17 2013-07-25 Universiteit Antwerpen Novel fap inhibitors
BR112014022435B1 (pt) * 2012-03-21 2023-02-14 Takeda Pharmaceutical Company Limited Inibidores de tfpi e métodos de uso
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
GB201402006D0 (en) 2014-02-06 2014-03-26 Oncomatryx Biopharma S L Antibody-drug conjugates and immunotoxins
CA2949936C (en) * 2014-06-10 2022-10-18 3B Pharmaceuticals Gmbh Conjugate comprising a neurotensin receptor ligand and use thereof
WO2016146174A1 (en) 2015-03-17 2016-09-22 Biontech Ag Compositions and methods for diagnosis and treatment of cancer
US11236123B2 (en) * 2016-01-20 2022-02-01 Polypeptide Laboratories Holding (Ppl) Ab Method for preparation of peptides with psWang linker
CR20180581A (es) 2016-06-10 2019-02-11 Bayer Pharma AG Complejos radio-farmacéuticos
CN105949282B (zh) * 2016-06-20 2020-06-16 郑州大学 一种靶向fap的抗血管生成肽z-gp-v2及其应用
CN106046121B (zh) * 2016-06-20 2020-06-16 郑州大学 一种靶向fap的抗血管生成肽z-gp-v1及其应用
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
JP2021500373A (ja) * 2017-10-23 2021-01-07 ザ・ジョンズ・ホプキンス・ユニバーシティ 線維芽細胞活性化タンパク質α（ＦＡＰ−α）を標的とする撮像剤および放射線療法用薬剤
PL3997103T3 (pl) * 2019-07-08 2025-03-24 3B Pharmaceuticals Gmbh Związki zawierające ligand białka aktywującego fibroblasty i ich zastosowanie

Similar Documents

Publication Publication Date Title
JP2024503635A5 (enExample)
IL289673B1 (en) Compounds comprising a fibroblast activation protein ligand and use thereof
CA2721470C (en) Somatostatin receptor 2 antagonists
IE67637B1 (en) Labeled Polypeptide Derivatives
US9533059B2 (en) Peptide radiotracer compositions
RU2115659C1 (ru) Производные нонапептидов или их солей с фармацевтически приемлемыми кислотами, способ их получения и фармацевтическая композиция
JP2020502051A5 (enExample)
AU2021204691B2 (en) Improved pharmacokinetics and cholecystokinin-2 receptor (CCK2R) targeting for diagnosis and therapy
US20250242064A1 (en) Cxcr4-targeting compounds, and methods of making and using the same
US12616761B2 (en) CXCR4-targeting compounds
CA2182670A1 (en) Peptide-chelator conjugates
JP2025503451A5 (enExample)
AU2021204347A1 (en) Somatostatin receptor antagonist compounds and methods of using the same
US20210330824A1 (en) Purification method and compositions
US9259496B2 (en) Technetium labelled peptides
WO2022002022A1 (zh) 一种放射性核素标记物及其应用
ES2929507T3 (es) Método para marcar una molécula directora biológica mediante conjugación con un radioisótopo adecuado para formación de imágenes por PET o SPECT
ES2309361T3 (es) Conjugados de complejos de tc y restos de direccionamiento y su uso en diagnostico por rmn.
US10548995B2 (en) Radiolabelling method
TW202541853A (zh) 增濃且安定之放射配體治療調製劑及包含彼之醫藥組成物
US20120178906A1 (en) Chelation of metals to thiol groups using in situ reduction of disulfide-containing compounds by phosphines
RU2022101907A (ru) Соединения, содержащие лиганд белка активации фибробластов, и их применение